- Investor's Business Daily•1 hour ago
Amgen will likely beat Eli Lilly, Alder and Teva to market with an antibody-blocking migraine med.
- TheStreet.com•3 hours ago
Amgen (AMGN) is partnering with Arrowhead Pharmaceuticals (ARWR) to develop two cardiovascular disease treatments using its RNAi therapy.
- MarketWatch•3 hours ago
Amgen Inc. and Arrowhead Pharmaceuticals Inc. said Thursday they have agreed to two cardiovascular collaborations. Under one agreement, Amgen will receive an exclusive license option to Arrowhead's proprietary ...
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||166.01 x 200|
|Ask||166.03 x 100|
|Day's Range||165.50 - 170.39|
|52wk Range||135.64 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||16.99|
|Avg Vol (3m)||2,840,878|
|Dividend & Yield||4.00 (2.33%)|